ZYUS Life Sciences Company Description

ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates in Canada, the United States, Australia, and the European Union.

The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2 clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer.

ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.

ZYUS Life Sciences Corporation

Country	Canada
Founded	2018
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
CEO	Brent Zettl

Contact Details

Address: Unit 204 Saskatoon, Ontario S7N 4L8 Canada
Phone	888 651 9987
Website	zyus.com

Stock Details

Ticker Symbol	ZYUS
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
SIC Code	2834

Key Executives

Name	Position
Brent H. Zettl	President, Chief Executive Officer, Secretary and Director
John M. Hyshka	Chief Financial Officer
Keith Carpenter CFA	Chief Strategy and Investment Officer
Michelle Gursky	Vice President of Legal Affairs
Dr. Lionel Marks de Chabris	Chief Medical Officer
Tim Miller	Director of Investor Relations and Capital Markets
Scott William Livingstone	Vice President of Clinical Research